Discussion at FDA's Nonprescription Drugs Advisory Committee meeting April 15 swung from potential OTC approval for Galderma Laboratories L.P.'s adapalene acne treatment to the broader issue of Rx-to-OTC switches and the level of safety assurance FDA should seek for ingredients potentially introducing new risks to the marketplace.
The NDAC voted unanimously to recommend OTC approval of Galderma Labs' adapalene gel 0
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on HBW Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?